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Therapeutic plasma exchange (TPE) is a process 
involving the extracorporeal separation of plasma 
from the cellular components of blood, discarding 
the plasma and exchanging it with replacement 
physiologic fluids such as albumin or fresh frozen 
plasma to maintain oncotic pressure and blood 
volume, and then returning this and the original 
cellular components of blood back to the patient’s 
circulatory system (4,5,7,19).
TPE is a extracorporeal therapy commonly used 
in the treatment of a variety of neurological, renal, 
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PURPOSE: The strongest effect of therapeutic plasma exchange (TPE) is achieved in diseases with immune 
and autoimmune genesis, hyperviscous conditions and intoxications of various origins. The aims of the 
study were to assess the long-term effect of TPE in the complex therapy of severe renal diseases and to high-
light therapeutic strategies necessary to achieve good clinical results. 
MATERIAL AND METHODS: During the period 1980-2010, TPE was carried out in the form of a complex 
treatment of 87 patients with immune nephropathies and 44 patients with malignant myeloma. The prima-
ry diseases were the following: chronic glomerulonephritis - 42, lupus nephropathy - 31, Henoch-Schönlein 
nephritis - 8, Wegener granulomatosis – four and Goodpasture syndrome - two patients. The diagnosis was 
confirmed after a puncture kidney biopsy in 72 (82,8%) patients with immune nephropathies. TPE was per-
formed using centrifugal or filtration methods. 
RESULTS: The patients with immune nephropathies underwent between 5 and 7 consecutive plasma ex-
changes daily or every two days. A three consecutive days of corticosteroid pulse therapy was initiated after 
last procedure followed by conventional immunosuppressive therapy. After serial TPE a significant decrease 
in anti-GMB antibodies and circulating immune complexes was detected. Continuous clinical and paraclin-
ical remission was achieved in 62,7% of the patients who received the combined treatment. 
CONCLUSION: TPE has a beneficial effect after being included in the complex treatment of patients with se-
vere immune nephropathies. The immunomodulation contributes to the successful management of severe 
ongoing autoimmune processes. In patients with hyperviscosity, ‘supporting’ TPE every 2 or 3 months is re-
quired to lower the increased viscosity, to prevent thromboembolic complications, and to slow-down ne-
phropathy progression.
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hematological, and other systemic diseases caused 
by circulating ‘toxic agents’ that can’t be cleared by 
other means. Most authors report effectiveness in 
about 50% of cases. The strongest effect is achieved 
in diseases with immune and autoimmune genesis, 
hyperviscous conditions and intoxications of various 
origins (1,10).
As plasma is used as the replacement 
(‘exchange’) fluid for a limited number of 
pathological conditions, ‘plasmapheresis’ is a more 
precise term than ‘therapeutic plasma exchange’, 
the latter of which implies not only plasma removal, 
but also replacement with plasma. Occasionally, 
the appropriate replacement fluid is colloid and/
or crystalloid instead of plasma. Because the use of 
‘TPE’ is more common, it is used synonymously with 
plasmapheresis (3).
Many primary renal diseases are associated with 
either antibody deposition within the glomerulus or 
an antibody associated autoimmunity, as may be seen 
with certain vasculitidies. Other immunoglobulins 
may be nephrotoxic or glomerulopathic (16). Here 
belongs the case with myeloma-related light chains 
or cryoglobulins.
The goal of plasma exchange is to mechanically 
extract pathogenic autoantibodies, immune 
complexes, cryoglobulins, myeloma light chains, 
endotoxin, cholesterol-containing lipoproteins and 
other unknown mediators. The basic premise of 
TPE is that removal of certain pathologic substances 
from the plasma will reduce further damage and 
may permit reversal of the pathologic process. 
Other potential benefits include unloading of the 
reticuloendothelial system (thereby enhancing 
endogenous removal of the circulating toxins) 
(18), stimulation of lymphocyte clones to enhance 
cytotoxic therapy (17), and the possibility of re-
infusing large volumes of plasma without the risk of 
intravascular volume overload.
In order to achieve the necessary 
immunomodulation it is required to carry out 
multiple consecutive TPE procedures. The plasma 
exchange has to be followed by immunosuppression 
in order to avoid the undesirable rebound effect 
which could compromise the achieved decrease in 
antibodies. Patients with counterindications for 
continuous immunosuppression report increased 
TPE effectiveness.
Dysproteinemias consist of a broad range of 
severe pathological states with the common thread 
of excessive production of an abnormal protein or 
paraprotein. Various clinical syndromes may arise, 
either from the underlying disease process, the excess 
paraprotein, or both. Clinical presentation depends 
upon the organ systems affected by the abnormal 
protein. Diseases included under the classification of 
dysproteinemias include cryoprotein-related diseases, 
Waldenström’s macroglobulinemia, hyperviscosity 
syndrome, monoclonal gammopathy, multiple 
myeloma (15), light chain disease, and amyloidosis. 
Plasmapheresis, often in conjunction with other 
therapies, is widely used to treat the dysproteinemias 
and their resulting clinical syndromes. Automated 
plasmapheresis that separates plasma from the 
cellular blood elements by centrifugation is used 
most commonly in the United States. Membrane 
separation and immunoadsorption techniques are 
more commonly used in Europe and Japan (2,8). 
Membrane separation and immunoadsorption allow 
the offending proteins to be removed more selectively 
from the patient’s plasma prior to the plasma being 
returned to the patient.
The purposes of the present study were to 
evaluate TPE long-term effect in the complex therapy 
of severe renal diseases and to highlight therapeutic 
strategies necessary to achieve good clinical results. 
MATERIAL AND METHODS
During the period 1980-2010 in the Clinic of 
Nephrology and Hemodialysis, St. Marina University 
Hospital of Varna (11,12), TPE was carried out in the 
form of a complex treatment in 87 patents, 38 males 
and 49 females, with immune nephropathies (Table 
1). Two methods of TPE were applied: centrifugal 
(with a Hemonetix M30 apparatus) and plasma 
filtration (with plasma filters PLASMAFLUX P-1 
and P-2). During the procedures, 1314±285 mL of 
plasma were extracted on average. Fluid replacement 
was achieved with plasma and colloid or crystalloid 
fluids in relatively equal proportions. This method 
was also applied to 44 patients, 31 males and 13 
females, with malignant myeloma with the intention 
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to lower the concentration of pathological proteins, 
to diminish the pathologically increased plasma 
viscosity (in order to enhance of microcirculation 
and to prevent vascular thrombosis) and to delay the 
development of myeloma nephropathy. More plasma 
per procedure was extracted in the treatment of these 
patients (an average of 2014±367 mL). The fluid 
replacement of plasma was achieved mainly by using 
crystalloid fluids. The diagnosis was confirmed after 
a puncture kidney biopsy in 72 (82,8%) patients with 
immune nephropathies. Kidney biopsies were not 
performed on patients with advanced renal failure.
RESULTS
Table 2 shows the patients according to their 
renal function.
In the patients with immune nephropathies 5 
to 7 consecutive plasma exchanges were carried out 
daily or every two days. A three consecutive days 
of corticosteroid pulse therapy was initiated after 
last procedure and was followed by conventional 
immunosuppressive therapy (18,19).
In the patients with Wegner’s granuloma, 7 to 
9 procedures were necessary in order to achieve the 
desirable effect (1,2). Most TPE (6) were carried out 
on two patients with Goodpasture syndrome (9), 
with 10 and 12 procedures, respectively.
After finishing the plasma exchanges a 
significant decrease in anti-GMB antibodies was 
detected along with a decrease in circulating immune 
complexes (Fig. 1).
Improved phagocytic activity of 
polymorphonuclear leukocytes after serial TPE 
was shown on Fig. 2. Continuous clinical and 
paraclinical remission was achieved in 62,7% of the 
patients on combined treatment in a timely manner. 
Additionally, delayed renal failure progression was 
reported with these patients compared to the control 
group (patients not undergoing ТPE) (13,16). 
No Diagnosis n
1. Chronic glomerulonephritis 42
2. Lupus nephropathy 31
3. Henoch-Schönlein nephritis 8
4. Wegener granulomatosis 4
5. Goodpasture syndrome 2
Total 87
Table 1. Patient‘s distribution according to their primary 
disease
No Renal function n
1. Normal renal function 61
2. Early stages of renal failure (1-2 stage) 12
3. Advanced renal failure 14
Table 2. Patient‘s distribution according to their renal 
function
Fig. 1. CIC values before and after serial TPE in patients 
with immune nephropathies
Fig. 2. Phagocite activity of polymorphonuclear cells 
before and after serial TPE in patients with immune 
nephropathies
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After completing TPE, a significant decrease 
in pathologically high plasma viscosity was detected 
in patients with myeloma nephropathy (Fig. 3). 
Additionally, the biological toxicity test indicated 
TPE pronounced detoxicating abilities (15) (Fig. 4).
DISCUSSION
This evidence corroborates the theory 
that early-stage renal failure, before the onset of 
permanent irreversible changes in kidneys, can be 
managed with combined treatment. Patients at stage 
3 and stage 4 renal failure do not demonstrate any 
desirable effects. Most of them shortly afterwards 
began hemodialysis treatment. 
CONCLUSION
Based on our findings and literature data 
available the conclusion can be drawn that the TPE 
has a beneficial effect after being included in the 
complex treatment of patients with severe immune 
nephropathies. The achieved immunomodulation 
contributes to the successful management of severe 
ongoing autoimmune processes. In patients with 
hyperviscosity, it is necessary to conduct ‘supporting’ 
TPE (14) every 2 or 3 months in order to reduce the 
increased viscosity, to prevent thromboembolic 
complications, and to slow-down nephropathy 
progression. 
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